Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Strahlentherapie und OnkologieOpen Access

Empiric stereotactic body radiotherapy for presumed early-stage lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

EDEsra DegerliKEKarim El-MaroukLKLukas Käsmann

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved overall survival in patients with presumed early-stage lung cancer, highlighting efficacy in high-risk groups.

Key Points

  • Overall survival after empiric SBRT was 50.7 months, indicating promising long-term outcomes.
  • Local control rates at 1, 2, and 3 years were notably high at 96.6%, 92.3%, and 87.1%, respectively.
  • Patients with lower comorbidity scores exhibited improved overall survival rates, suggesting significance in treatment outcomes.
  • Chronic obstructive pulmonary disease was identified as a potential risk factor for treatment-related toxicity.

Cite This Study

Degerli et al. (2025) studied this question.

synapsesocial.com/papers/68c240deb210217d6479cc1ahttps://doi.org/10.1007/s00066-025-02434-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Stereotactic body radiation therapy for early-stage non-small cell lung cancer: a single-institutional retrospective analysis of outcomes and prognostic factors2025
  2. 2From protocol to practice: long-Term outcomes of single-Fraction stereotactic body radiotherapy for primary non-Small cell lung cancer2025
  3. 3A monocentric retrospective analysis of 10‑year overall survival after stereotactic body radiotherapy for medically inoperable non‑small cell lung cancer2025
  4. 4Long-term clinical results of early-stage lung cancer patients treated with risk-adapted stereotactic body radiotherapy using LINAC or CyberKnife2025 · 5 citations
  5. 5Immunological biomarkers for precision stereotactic body radiation therapy in early-stage non-small cell lung cancer: a systematic review2026